Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS)
CUSIP: 00461U105
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, $0.00001 par value
- Shares outstanding
- 138,752,791
- Total 13F shares
- 85,675,311
- Share change
- -6,186,333
- Total reported value
- $162,782,120
- Price per share
- $1.90
- Number of holders
- 103
- Value change
- -$11,317,612
- Number of buys
- 40
- Number of sells
- 47
Quarterly Holders Quick Answers
What is CUSIP 00461U105?
CUSIP 00461U105 identifies ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 00461U105:
Top shareholders of ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BML Capital Management, LLC |
13F
|
Company |
10%
|
14,250,000
|
$20,235,000 | — | 30 Jun 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
6.9%
|
9,627,304
|
$13,670,772 | — | 30 Jun 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
6.4%
|
8,888,888
|
$12,622,221 | — | 30 Jun 2025 | |
| Adage Capital Management, L.P. |
13D/G
|
— |
4.9%
|
5,278,144
|
$10,028,474 | -$5,554,080 | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.8%
|
6,662,063
|
$9,460,130 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
4%
|
5,514,879
|
$7,831,128 | — | 30 Jun 2025 | |
| Rock Springs Capital Management LP |
13D/G
13F
|
Company |
4.7%
|
5,046,309
|
$7,720,853 | $0 | 31 Mar 2025 | |
| Decheng Capital LLC |
13F
|
Company |
2.9%
|
4,041,736
|
$5,739,265 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
13D/G
|
Company |
3.5%
from 13D/G
|
3,837,380
|
$5,449,080 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2.6%
|
3,540,192
|
$5,027,072 | — | 30 Jun 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
2%
|
2,800,282
|
$3,976,400 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
2,464,779
|
$3,500,928 | — | 30 Jun 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
1.8%
|
2,433,850
|
$3,453,000 | — | 30 Jun 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.7%
|
2,292,449
|
$3,255,278 | — | 30 Jun 2025 | |
| Logos Global Management LP |
13F
|
Company |
1.3%
|
1,850,000
|
$2,627,000 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.1%
|
1,464,778
|
$2,079,985 | — | 30 Jun 2025 | |
| Palo Alto Investors LP |
13F
|
Company |
1%
|
1,390,028
|
$1,973,840 | — | 30 Jun 2025 | |
| Bollard Group LLC |
13F
|
Company |
0.97%
|
1,352,276
|
$1,920,000 | — | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.82%
|
1,143,806
|
$1,624,204 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.73%
|
1,006,893
|
$1,429,788 | — | 30 Jun 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.73%
|
1,006,549
|
$1,429,300 | — | 30 Jun 2025 | |
| Aldebaran Capital, LLC |
13F
|
Company |
0.72%
|
993,698
|
$1,411,051 | — | 30 Jun 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.57%
|
797,134
|
$1,131,930 | — | 30 Jun 2025 | |
| Anand Mehra |
3/4/5
|
Director |
—
mixed-class rows
|
757,173
mixed-class rows
|
$1,098,616 | — | 05 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.55%
|
766,255
|
$1,088,083 | — | 30 Jun 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.55%
|
764,300
|
$1,085,306 | — | 30 Jun 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.54%
|
749,660
|
$1,064,517 | — | 30 Jun 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.45%
|
623,792
|
$885,785 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.37%
|
509,350
|
$723,277 | — | 30 Jun 2025 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
0.35%
|
491,300
|
$697,646 | — | 30 Jun 2025 | |
| Andrew N. Schiff |
3/4/5
|
Director |
—
mixed-class rows
|
490,765
mixed-class rows
|
$691,011 | — | 05 Jun 2025 | |
| CANTOR FITZGERALD, L. P. |
13F
|
Individual |
0.33%
|
451,120
|
$640,590 | — | 30 Jun 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.32%
|
443,319
|
$629,513 | — | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
0.32%
|
442,247
|
$627,991 | — | 30 Jun 2025 | |
| Aisling Capital Management LP |
13F
|
Company |
0.31%
|
434,455
|
$616,926 | — | 30 Jun 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.28%
|
390,583
|
$554,628 | — | 30 Jun 2025 | |
| Joseph Monahan |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
570,280
mixed-class rows
|
$550,792 | — | 01 Mar 2025 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.23%
|
321,817
|
$456,980 | — | 30 Jun 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.2%
|
277,259
|
$393,708 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.19%
|
261,298
|
$371,043 | — | 30 Jun 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.17%
|
237,830
|
$337,718 | — | 30 Jun 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.16%
|
215,262
|
$305,672 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.15%
|
207,273
|
$294,607 | — | 30 Jun 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.13%
|
184,585
|
$262,111 | — | 30 Jun 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.12%
|
166,367
|
$237,000 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.11%
|
156,572
|
$222,333 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.11%
|
156,337
|
$221,998 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.11%
|
153,172
|
$217,504 | — | 30 Jun 2025 | |
| Frank Ruffo |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
201,883
|
$211,977 | — | 10 Mar 2022 | |
| Invesco Ltd. |
13F
|
Company |
0.1%
|
135,329
|
$192,167 | — | 30 Jun 2025 |
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q3 2025
As of 30 Sep 2025,
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by
103 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
85,675,311 shares.
The largest 10 holders included
BML Capital Management, LLC, Vivo Capital, LLC, VANGUARD GROUP INC, BlackRock, Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., Rock Springs Capital Management LP, MORGAN STANLEY, Decheng Capital LLC, GEODE CAPITAL MANAGEMENT, LLC, and D. E. Shaw & Co., Inc..
This page lists
103
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
95
Q3 2025 holders
103
Holder diff
8
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.